Gonzalo Labarca1,2,3, Erik Folch3,4, Michael Jantz3,5, Hiren J Mehta3,5, Adnan Majid3,6, Sebastian Fernandez-Bussy3,7. 1. 1 Facultad de Medicina, Universidad San Sebastian, Concepcion, Chile. 2. 2 Complejo Asistencial Dr. Victor Rios Ruiz, Los Angeles, Chile. 3. 3 Evidence-based Medicine in Pulmonology (EBMIP): International Working Group, Los Angeles, Chile. 4. 4 Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts. 5. 5 Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida. 6. 6 Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; and. 7. 7 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, Florida.
Abstract
RATIONALE: Endobronchial ultrasound and transbronchial needle aspiration (EBUS-TBNA) are commonly used for the diagnosis and mediastinal staging of lung cancer. Molecular markers are becoming increasingly important in patients with lung cancer to define targetable mutations suitable for personalized therapy, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species proto-oncogene (ROS1), and programmed death-ligand 1 (PD-L1). OBJECTIVES: To evaluate the adequacy of EBUS-TBNA-derived tissue for molecular analysis. METHODS: We searched the MEDLINE, LILACS, www.clinicaltrials.gov , and Epistemonikos databases through January 2018. DATA EXTRACTION: Two independent reviewers performed the data search, quality assessment, and data extraction. We included both prospective and retrospective studies; risk of bias was evaluated using the ROBINS-I tool. The primary outcome was the proportion of adequate samples obtained by EBUS-TBNA for molecular analysis. Data were pooled by using a binary random effects model. Finally, evidence was rated by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. RESULTS: A total of 33 studies including 2,698 participants were analyzed. In 28 studies that evaluated EBUS-TBNA for the identification of EGFR mutations, the pooled probability of obtaining a sufficient sample was 94.5% (95% confidence interval CI], 93.2-96.4%). For identification of ALK mutations, the pooled probability was 94.9% (95% CI, 89.4-98.8%). Finally, the prevalence of EGFR mutation was 15.8% (95% CI, 12.1-19.4%), and the prevalence of ALK mutation was 2.77% (95% CI, 1.0-4.8%). Data for ROS1 and PD-L1 mutations were not suitable for meta-analysis. CONCLUSIONS: EBUS-TBNA has a high yield for molecular analysis of both EGFR and ALK mutations. However, the suitability of TBNA samples for next-generation sequencing is uncertain and should be explored in further studies. Clinical trial registered with PROSPERO (CRD42017080008).
RATIONALE: Endobronchial ultrasound and transbronchial needle aspiration (EBUS-TBNA) are commonly used for the diagnosis and mediastinal staging of lung cancer. Molecular markers are becoming increasingly important in patients with lung cancer to define targetable mutations suitable for personalized therapy, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), reactive oxygen species proto-oncogene (ROS1), and programmed death-ligand 1 (PD-L1). OBJECTIVES: To evaluate the adequacy of EBUS-TBNA-derived tissue for molecular analysis. METHODS: We searched the MEDLINE, LILACS, www.clinicaltrials.gov , and Epistemonikos databases through January 2018. DATA EXTRACTION: Two independent reviewers performed the data search, quality assessment, and data extraction. We included both prospective and retrospective studies; risk of bias was evaluated using the ROBINS-I tool. The primary outcome was the proportion of adequate samples obtained by EBUS-TBNA for molecular analysis. Data were pooled by using a binary random effects model. Finally, evidence was rated by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. RESULTS: A total of 33 studies including 2,698 participants were analyzed. In 28 studies that evaluated EBUS-TBNA for the identification of EGFR mutations, the pooled probability of obtaining a sufficient sample was 94.5% (95% confidence interval CI], 93.2-96.4%). For identification of ALK mutations, the pooled probability was 94.9% (95% CI, 89.4-98.8%). Finally, the prevalence of EGFR mutation was 15.8% (95% CI, 12.1-19.4%), and the prevalence of ALK mutation was 2.77% (95% CI, 1.0-4.8%). Data for ROS1 and PD-L1 mutations were not suitable for meta-analysis. CONCLUSIONS: EBUS-TBNA has a high yield for molecular analysis of both EGFR and ALK mutations. However, the suitability of TBNA samples for next-generation sequencing is uncertain and should be explored in further studies. Clinical trial registered with PROSPERO (CRD42017080008).
Authors: Amrik S Ray; Changyi Li; Terrence E Murphy; Guoping Cai; Katy L B Araujo; Kyle Bramley; Erin M DeBiasi; Margaret A Pisani; Isabel Oliva Cortopassi; Jonathan T Puchalski Journal: Ann Thorac Surg Date: 2019-10-05 Impact factor: 5.102
Authors: Adam H Fox; James R Jett; Upal Basu Roy; Bruce E Johnson; Jennifer C King; Nikki Martin; Raymond U Osarogiagbon; M Patricia Rivera; Lauren S Rosenthal; Robert A Smith; Gerard A Silvestri Journal: Chest Date: 2021-06-26 Impact factor: 9.410
Authors: Marija Karadzovska-Kotevska; Hans Brunnström; Jaroslaw Kosieradzki; Lars Ek; Christel Estberg; Johan Staaf; Stefan Barath; Maria Planck Journal: PLoS One Date: 2022-02-02 Impact factor: 3.240
Authors: George Tsaknis; Muhammad Naeem; Sridhar Rathinam; Alison Caswell; Jayne Haycock; Jane McKenna; Raja V Reddy Journal: J Bronchology Interv Pulmonol Date: 2022-04-01